RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Oncology Support Anti-Emetic)
February 25, 2013 08:00 ET
|
RedHill Biopharma Ltd.
Following a successful comparative bioavailability trial, the Company met with the FDA to discuss its planned New Drug Application (NDA) filing for RHB-102
Company plans to file the RHB-102...
RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results
February 19, 2013 11:39 ET
|
RedHill Biopharma Ltd.
Key Planned Milestones for 2013 Include Commencement of Phase III and Phase II/III Studies With RHB-104 (Crohn's Disease) and RHB-105 (H. pylori), Respectively, and New Drug Application (NDA)...
RedHill Biopharma Announces Notice of Allowance From the United States Patent and Trademark Office for Its Cardio Drug RHB-101
February 19, 2013 09:19 ET
|
RedHill Biopharma Ltd.
RHB-101 is a proprietary, controlled release, once-daily formulation of carvedilol for the treatment of hypertension, congestive heart failure and left ventricular dysfunction
The...
RedHill Biopharma Announces Date of 2012 Financial Results and Corporate Update Conference Call
February 14, 2013 09:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 14, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late...
RedHill Biopharma Announces Issuance of New U.S. Patent and Provides Update on RHB-104 for Treatment of Crohn's Disease
January 07, 2013 09:00 ET
|
RedHill Biopharma Ltd.
Patient Recruitment in an Initial Phase III Study is Planned to Commence Q2/2013; Multi-Site Initiation Process is Underway; Newly Issued Patent Expires no Earlier Than 2029
Additional Planned and...
RedHill Biopharma Announces NASDAQ Listing and Commencement of Trading Under the Ticker "RDHL"
December 27, 2012 09:00 ET
|
RedHill Biopharma Ltd.
Trading on NASDAQ to Commence Today, Thursday, December 27th, 2012 Following Final Approvals From SEC and NASDAQ
The Listing Does Not Include Capital Raising as Part of the Registration Process...